This resource includes hand-crafted patent highlights featuring synthetically lethal Pol inhibitors from linkedin_mention(urn:li:organization:1603|AstraZeneca) and linkedin_mention(urn:li:organization:1399|GSK) , SARM1 Inhibitors for neurodegenerative indications and our best guess at the identity of linkedin_mention(urn:li:organization:163993|Gilead Sciences) ' small molecule GLP-1R agonist GS-4571 Full article | Drug Hunter's 2023 Patent Review of GLP-1R Agonists June 2024 Patent Highlights: GLP-1R Agonists, Pol Inhibitors, Non-Ab PD-L1 Inhibitors and More
There are three forms of brandingtheres a company branding, then molecule branding and then category branding, he says, adding that the innovators have effectively seeded all three layers in the minds of consumers through their high-decibel brand campaigns, including billboards, television, print, social media, and celebrity marketing, over the last 12 months
Dihexa Is a synthetic oligopeptide drug that is being studied for its potential to treat neurodegenerative diseases, particularly Alzheimers disease
Owens RJ, et al
MSM has been shown to exhibit anti-inflammatory, antioxidant, and anti-cancer activity
J., Li, Y., Lahiri, D
